Compare Cytokinetics Inc (CYTK) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs CarMax, Inc — how do they compare? Cytokinetics Inc trades at $62.68 (market cap $8.62B), while CarMax, Inc trades at $52.95 (market cap $7.64B). The key difference: Cytokinetics Inc and CarMax, Inc are close in size by market cap, and CarMax, Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and CarMax, Inc for 49 Days on average.
| CYTK | KMX | |
|---|---|---|
Market Cap | $8.62B | $7.64B |
Volume | 2,594,626 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $64.22 |
52-Week Low | $54.76 | $30.88 |
Typical Hold Time | 19 Days | 49 Days |
Enterprise Value | $8.72B | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
CarMax (KMX) trades at $53.28, down 3.64% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth (Q2 2026 revenue up 19.5% to $7.9B) but thin net margins (1.06%). Analyst consensus leans cautious with 62% hold ratings, though price targets suggest 10.5% upside to $58.89. Recent leadership appointments and strategic updates signal management's focus on growth execution.
Outlook hinges on CarMax's ability to sustain unit sales momentum while improving profitability. The stock offers value appeal (P/S 0.28) but faces execution risks from high debt ($18.1B long-term) and competitive pressures. Near-term catalysts include November's strategic webcast and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
